SynthesisFrontiers in medicine2026
Prediction models for sarcopenia in older adults in China: a scoping review.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This scoping review synthesized research on sarcopenia prediction models for older adults in China to identify key limitations constraining their clinical applicability. Methods: Adhered to the Arksey and O'Malley framework and the PRISMA-ScR guidelines for this scoping review. Sarcopenia prediction models were systematically retrieved from PubMed, Embase, Web of Science, CNKI, and Wanfang, from inception to December 31, 2024. Two reviewers independently screened the literature and extracted data. Eligible studies were narratively synthesized. Results: This review identified 20 articles encompassing 34 prediction models. The reported prevalence of sarcopenia across studies ranged from 12 to 54.17%. Logistic regression and machine learning were the predominant modeling techniques. The number of predictor variables per model ranged from 3 to 8. The most frequently included predictors were age ( Conclusion: Despite the rapid growth of sarcopenia prediction models in recent years, this review reveals persistent deficiencies in variable selection, methodological rigor, and external validation, which collectively limit their clinical applicability. Addressing these issues is essential for developing predictive tools that are statistically robust, clinically applicable, and tailored to China's aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.